NU-9, a novel, non-toxic compound, targets upper motor neurons and reverses damage associated with ALS within 60 days of treatment.
Findings can help researchers test for the CAPN1 mutations associated with some forms of HSP.
Researchers identify a genetic mutation in almost 75 percent of subjects with autosomal recessive HSP, half of which were in genes never previously linked with human disease.
